AbCellera Biologics Inc. (ABCL) Profit Margins
Over the twelve months to 2026-06-30, AbCellera Biologics Inc. (ABCL) had operating margin -340.3%, net margin -248.8%, free cash flow margin -180.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ABCLAbCellera Biologics Inc.Follow ABCL — free
—
Price chart with a free account
- Market cap
- 3.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 82.2% | 78.3% | 35.8% | — | 70.5% | — | |
| Operating margin | 54.5% | 44.6% | -623.8% | -1091.7% | -289.0% | -340.3% | |
| Net margin | 40.9% | 32.7% | -385.0% | -564.8% | -194.9% | -248.8% | |
| FCF margin | 49.6% | 42.6% | -317.7% | -648.4% | -231.7% | -180.8% |
USD billions · SEC XBRL
AbCellera Biologics Inc. — questions
- What is AbCellera Biologics Inc.'s operating margin?
- -340.3% over the twelve months to 2026-06-30.
- What is AbCellera Biologics Inc.'s net profit margin?
- -248.8% over the twelve months to 2026-06-30.
Every figure on this page comes from AbCellera Biologics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.